|Location Uncertainty||Horizontal: 7.5 km; Vertical 5.|
1. Researchers at the Indian Institute of Technology (IIT) Guwahati has developed a scaffold made of silk composite functionalised with copper-doped bioactive glass to facilitate faster bone regeneration.
The scaffold seeded with stem cells was found to differentiate into bone cells, facilitate growth of blood vessels and successfully integrate the newly formed bone cells with the native bone.
The research team developed the silk composite by adding chopped silk fibre to liquid silk. Unlike pure silk, the silk composite has greater strength. The addition of bioglass further enhanced the strength of the composite.
The team plans to undertake trials on larger animals now, and is hopeful to get regulatory clearance soon.
2. AstraZeneca is a global, science-led biopharmaceutical company, announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment of adults with hyperkalaemia.
Hyperkalaemia is a serious condition characterised by elevated potassium levels in the blood associated with cardiovascular, renal and metabolic diseases.
3.Proton pump inhibitors (PPIs) are used to suppress acid production in the stomach and are among the most widely sold drugs in the world, but a new study reveals that long-term use of the medicine can increase stomach cancer risks by almost 250 percent. Helicobacter pylori, carried by more than half of the world’s population – most often harmlessly, but in a small percentage of people, the bug has been tied to the development of stomach cancer.
Previous research found that people with an ongoing Helicobacter pylori infection taking a PPI stood a greater chance of developing a precursor to stomach cancer, called atrophic gastritis.
4.Microsoft is partnering with Seattle biotech company Adaptive Bio-technologies on a year-long project to build a universal blood test that can screen for dozens or even hundreds of diseases at a time, all by decoding the information in the immune system.
Microsoft is investing an undisclosed sum in Adaptive and is offering the company cloud computing and machine learning services. The combined value of those two is in the hundreds of millions of dollars. If the project is a success, it would be a radical change to how we diagnose diseases from cancer to multiple sclerosis and would mark a new era for health technology. Revolution in diagnostic aspects specially on diseases that are often diagnosed in very late stages, like pancreatic and ovarian cancer; autoimmune diseases that are typically hard to diagnose, like multiple sclerosis; and infectious diseases that can remain in a person’s system and reoccur, like chronic Lyme disease.
5.AstraZeneca is working in collaboration with the molecular diagnostics firm Myriad Genetics’ for its test myChoice HRD Plus to identify advanced ovarian cancer patients who might benefit from maintenance treatment using Lynparza (olaparib) and Avastin (bevacizumab).
The new deal is part of an ongoing collaboration formed by the firm with AstraZeneca in 2007 for the development of a companion diagnostic test to detect individuals for treatment with olaparib.
myChoice HRD Plus is a comprehensive homologous recombination deficiency test for the detection of loss of a tumour’s ability to repair breaks in double-stranded DNA. The test includes loss of heterozygosity, telomeric allelic imbalance and large-scale state transition technologies, along with 90 additional genes and molecular markers.
6. GHIT Fund is an international public-private partnership spearheaded by the Government of Japan, the Bill and Melinda Gates Foundation, Wellcome Trust and a group of pharmaceutical companies. GHIT Fund has awarded the University of Florida and partners in the United States and Japan $3.2 million to advance a promising vaccine to prevent transmission of malaria. New grant from the Global Health Innovative Technology Fund will further development of processes to move the vaccine from the experimental stage to human trials and, ultimately, a clinical treatment.
Rhoel Dinglasan, an associate professor of infectious diseases in UF’s College of Veterinary Medicine and the university’s Emerging Pathogens Institute, has spent years developing a malaria transmission blocking vaccine, or TBV.
7. Merck to introduce on April 17-19, in New York City, US three new products for the flexible manufacturing of biologics at INTERPHEX, .
Pellicon® Capsule with Ultracel® Membrane. This first-of-its-kind single-use tangential flow filtration device is used for bio-processing of antibody-drug conjugates and monoclonal antibodies.
Millipak® Final Fill Filter. These filters provide maximum product yield in high-value, small-volume processing.
Mobius® Power MIX 2,500-Liter and 3,000-Liter large-scale single-use mixers. These mixing systems combine high-performance technology with design elements that make them easy to use when mixing the most challenging buffers, media and bio-pharmaceutical ingredients.
Kenichiro Yoshida take control of Sony on Sunday. Yoshida to have unique strategy need mass friendly a different stance. Thus corporate e giants onserving market.scientific innovation perpuate as he picks up the baton from President and CEO Kazuo Hirai.
Popular posts from this blog
The Last Days of Mahatma Gandhi: Manoj JhaON JANUARY 25, 2018 BY NARESH SAGARLEAVE A COMMENTEDIT Monday, 29 January 2018 at 6 pm Anhad Baat Cheet in collaboration with Oxford Bookstore invites you to A talk (Remembering Mahatma Gandhi On the eve of 70 year of his Martyrdom) titled The Last Days of Mahatma Gandhi by Manoj K Jha Manoj K. Jha is a Professor at Department of Social Work, University of Delhi. His research interests revolve around methodological and conceptual issues of social protest movements, minorities and marginalised communities. He is also a visiting faculty to School of Planning and Architecture, Delhi. YOU ARE WELCOME OxfordBookstore N 81, Connaught Place, New Delhi – 110 001 RSVP: Manash – 9953970829 firstname.lastname@example.org m www.oxfordbookstore.com
India is committed to improving ease of doing business:ON JANUARY 26, 2018 BY NARESH SAGARLEAVE A COMMENTEDIT Housing and Urban Affairs Minister Hardeep Singh Puri today said India is committed to improving ease of doing business. Addressing the 42nd Joint Meeting of India- Japan Business Cooperation Committee in New Delhi, Mr Puri said, India offers opportunities to Japan in the fields like Make In India, Digital India, Skill India and Smart City Project. He said, during the last three years, the government has taken a lot of initiatives to improve economic growth, investors confidence and business sentiments in the country. He said, India is the most liberal FDI regime in the world and during 2016-17, the country received foreign direct investment inflow to the tune of 60 billion dollars. Nation celebrates 69th Republic DayON JANUARY 26, 2018 BY NARESH SAGARLEAVE A COMMENTEDIT Nation is celebrating its 69th Republic Day today. The main function was organized at Rajpath in the nationa…
Ambani Antilia Kids See ‘Bright Future for Reliance’ON DECEMBER 26, 2017 BY NARESH SAGARLEAVE A COMMENTEDIT Ambani Antilia Kids See ‘Bright Future for Reliance’ Not India December25, 2017 (C) Ravinder Singhprogressindia2015@gmail.com In this special message to Antilia Kids brought up in Manipulated-Scammed Reliance Organization that Future for RIL is DARK not bright. Read ‘Polyester Prince’for founder’s history. Read stories of 2nd Gen in KG Basin, RCom, RPower, RInfra Failures etc. Companies to Be Inherited by 3rd Gen Antilia Kids are most VULNERABLE. Directors of RIL are their Mom & Pop plus some relatives. NIKE Directors have $10 Trillion Skills.* [In Next Report] NIKE $103b vs RIL $93b https://s1.q4cdn.com/806093406/files/doc_financials/2017/ar/docs/nike-shareholders-letter-2017.pdf For all the Scams & Manipulations RIL is worth $10b Less than NIKE valued at $103b to RIL valued at $93b. [Both Present Day Costs] We are supplied by approximately 127 footwear factories located in…